Bolt Biotherapeutics (NASDAQ:BOLT) Posts Quarterly Earnings Results, Hits Estimates

Bolt Biotherapeutics (NASDAQ:BOLT) posted its quarterly earnings data on Monday. The company reported ($0.38) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.38), Zacks reports. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%.

Bolt Biotherapeutics Stock Performance

BOLT opened at $0.44 on Tuesday. The company has a 50 day simple moving average of $0.47 and a two-hundred day simple moving average of $0.56. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The firm has a market cap of $16.75 million, a P/E ratio of -0.26 and a beta of 0.94. Bolt Biotherapeutics has a 1-year low of $0.38 and a 1-year high of $1.56.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.